

Chemical Biology approach to identification of a small-molecule inhibitor of BamA function



MERCK

INVENTING FOR LIFE

March 2020

D. M. Rothman on behalf of team

Acknowledgements

Princeton University

Elizabeth M. Hart
Angela M. Mitchell
Anna Konovalova
Marcin Grabowicz
Jessica Sheng
Thomas J. Silhavy

Merck

Xiaoqing Han
Frances P. Rodriguez-Rivera
Adam G. Schwaid
Juliana C. Malinverni
Carl J. Balibar
Smaranda Bodea
Qian Si
Hao Wang

Michelle F. Homsher
Ronald E. Painter
Anthony K. Ogawa
Holly Sutterlin
Terry Roemer
Todd A. Black
Deborah M. Rothman
Scott S. Walker

Gram-negative Challenge

Antibiotic resistance remains an increasing threat to public health and three of the five urgent threat pathogens are gram-negative bacteria

The Threat of Antibiotic Resistance in the United States

Antibiotic resistance—when germs (bacteria, fungi) develop the ability to defeat the antibiotics designed to kill them—is one of the greatest global health challenges of modern time.

New National Estimate*

Each year, antibiotic-resistant bacteria and fungi cause at least an estimated:	+	<i>Clostridioides difficile</i> is related to antibiotic use and antibiotic resistance:
2,868,700 infections		223,900 cases
35,900 deaths		12,800 deaths

New Antibiotic Resistance Threats List

Updated urgent, serious, and concerning threats—totaling 18

5 urgent threats	2 new threats	NEW: Watch List with 3 threats
-------------------------	----------------------	--

Antibiotic resistance remains a significant One Health problem, affecting humans, animals, and the environment. Data show infection prevention and control is saving lives—especially in hospitals—but threats may undermine this progress without continued aggressive action now.



CARBAPENEM-RESISTANT ACINETOBACTER

THREAT LEVEL URGENT

8,500 Estimated cases in hospitalized patients in 2017	700 Estimated deaths in 2017	\$281M Estimated attributable healthcare costs in 2017
--	--	--

CARBAPENEM-RESISTANT ENTEROBACTERIACEAE

THREAT LEVEL URGENT

13,100 Estimated cases in hospitalized patients in 2017	1,100 Estimated deaths in 2017	\$130M Estimated attributable healthcare costs in 2017
---	--	--

DRUG-RESISTANT NEISSERIA GONORRHOEAE

THREAT LEVEL URGENT

550,000 Estimated drug-resistant infections each year	1.14M Total new infections each year	\$133.4M Annual discounted lifetime direct medical costs
---	--	--

Gram-negative Challenge





Image: cdc.gov

Gram-negative antibiotic discovery is additionally challenged by the Outer Membrane (OM)


- Asymmetric bilayer (Outer Leaflet = lipopolysaccharides, Inner Leaflet = phospholipids)
- MDR efflux pumps

Targeting the OM as a strategy




New antibiotics target bacterial envelope
M. C. Sousa, Nature **2019** v576 p389


Approach and Identification of MRL-494



Hypothesis: compounds with similar activity on efflux and permeability competent and impaired cells may evade efflux and the OM permeability barrier due to chemical nature and/or the surface location of their target



Profiling MRL-494



Spectrum activity of MRL-494

Classification	Description	MIC (μM)
Gram-negative	<i>E. coli</i> (WT)	25
	<i>E. coli</i> (ΔtolC)	25
	<i>E. coli</i> (ΔtolC , <i>lpxC101</i>)	25
	<i>K. pneumoniae</i>	100
	<i>A. baumannii</i> (WT)	200
	<i>A. baumannii</i> (ΔlpxC)	200
	<i>P. aeruginosa</i> (WT)	100
	<i>P. aeruginosa</i> (efflux deficient)	100
Gram-positive	<i>Staphylococcus aureus</i> (methicillin-resistant)	12.5
	<i>Bacillus subtilis</i> rpoB18	25
HeLa	Mammalian – ClickIt EdU (EC50)	> 99


Not efflux substrate
No permeability issue

Initiating MOA Deconvolution


FM4-64: membrane
DAPI: nucleic acid
Sytox: nucleic acid, non-permeable
2hr compound exposure

Bacterial Cytological Profiling (Linnaeus)

2% DMSO




1X MIC




- Membrane foci at the cell poles
- Some abnormally long

3X MIC



- Some cells lysing

5X MIC



- Cells permeabilized
- Cells lysing

*The compound does not closely match known controls.
Suggests novel MOA.*

MRL-494 impacts OM and decreases OMP abundance


MRL-494 potentiates rifampicin

Condition	<i>E. coli</i> MIC (uM)	
	WT	lpxC101
Rifampicin	25.000	< 0.049
Rifampicin + 6.25 uM MRL-494	0.195	---

Rifampicin: RNA polymerase inhibitor which does not penetrate OM

lpxC101: mutation which decreases LPS on OM and potentiates rifampicin activity

MRL-494 decreases OMPs




1.5h treatment

Observe increase in DegP
Indication of extracellular envelope stress


MRL-494 increases stress response

Batimastat targets RseP and inhibits the σ^E pathway



PNAS 2018 115 (28) E6614


MRL-494 increases σ^E activity



σ^E -GFP readout


MRL-494 inhibits OMP biogenesis

Batimastat targets RseP and inhibits the σE pathway




PNAS 2018 115 (28) E6614

Batimastat potentiates MRL-494





- MRL-494 prevents formation of trimer & decreases total amount of LamB
- Batimastat increases accumulation of unfolded OMP

MRL-494 stabilizes BamA by 2D-CETSA™




Cellular Thermal Shift Assay: BamA




BamA genetic status impacts resistance to MRL-494

BamA^{E470K} confers resistance





BamA WT OE confers resistance




BamA^{E470} Mutation

Observed 470 amino acid charge impacts MRL-494 activity and BamA stability




BamA^{E470} Mutation

Batimastat targets RseP and inhibits the σ E pathway




PNAS 2018 115 (28) E6614

E470K mutant suppresses batimastat/MRL-494



BamA^{E470} mutation may act as hypermorph




Pulse chase experiment recently reported from Kahne, et. al.

- * = approximately 50% of the LptD has converted to the mature form, containing the [1,3][2,4] disulfide bond configuration
- BamA WT ~ 50 min
BamA^{E470G} ~ 25 min

Summary

- ✓ MRL-494 identified as tool which functionally inhibits BamA in Gram-negative bacteria
- ✓ BamA^{E470K} identified as mutant which demonstrates MIC shift for MRL-494
- ✓ BamA^{E470K} does not have impaired function in the assembly of wild-type OMPs under laboratory conditions
- ✓ BamA^{E470K} does have both altered conformation and activity
 - Correlates with resistance to MRL-494
 - Neither the conformational change nor the altered activity sufficient to explain the MRL-494 resistance
- ✓ Recent publication demonstrates opportunity for how MRL-494 could be a mechanistic tool to inform on new biology – how would different mutations impact MRL-494 activity?



THANK YOU

MERCK




Bacterial Cytological Profiling

Linnaeus




2% DMSO Control

- For BCP, we grew samples of *E.coli ΔtolC* in rich media (LB) at 30°C to an OD₆₀₀ ~0.15. These cultures were then split and each sample treated with the appropriate concentration of test compound.
- We collected samples after 30 minutes or 2 hours of exposure, stained and then imaged them.
- Below, we have included images showing the predominant phenotype produced by each of the test compounds at 2 hours of exposure.

	Merck <i>ΔtolC</i> MIC (μM)	Linnaeus <i>ΔtolC</i> MIC (μM)
L-494	12.5	12.5




L-494 at 1X, 3X and 5X the MIC



BamA^{E470K} shifts MRL-494 potency

BamA^{E470K} shifts MIC to solubility limit



BamA^{E470K} shifts MIC in Δ *bamB*

